# A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

> **NCT02761642** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 200 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Epoetin Beta

## Key facts

- **NCT ID:** NCT02761642
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02-29
- **Primary completion:** 2007-03-31
- **Final completion:** 2007-03-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02761642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02761642, "A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02761642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*